Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III (TRACE III)
A Phase 3, Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint (PROBE) Controlled Trial of Tenecteplase Versus Standard Medical Treatment for Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion With Perfusion Mismatch up to 24 Hours of Symptom Onset
Sponsor: Beijing Tiantan Hospital
A PHASE3 clinical study on Ischemic Stroke, Acute, this trial is completed. The trial is conducted by Beijing Tiantan Hospital and has accumulated 8 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2024 — May 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Aug 2023 — Mar 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Tiantan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .